CagriSema (Cagrilintide + Semaglutide) Supplement Protocol
Evidence-based nutrient depletion risks and supplement recommendations for Developmental combination users.
Cagrilintide is an amylin analog that co-targets the GLP-1 receptor, potentially enhancing satiety and weight loss effects with semaglutide. Combined, they act on GLP-1 receptors.
Clinical trials ongoing (REDEFINE program, Phase 2 completed, Phase 3 ongoing as of April 2026). Not yet FDA approved.
Nutrient Depletion Risks
8 nutrients affected by CagriSema (Cagrilintide + Semaglutide)
Reduced caloric intake, rapid weight loss.
Reduced food intake, potential GI side effects.
Inadequate protein intake due to appetite suppression and risk of lean mass loss with significant weight loss.
Reduced food intake.
Reduced intake, potential for impaired absorption.
Reduced intake, potential for deficiency with prolonged caloric restriction and GI symptoms.
Reduced food intake. GI side effects may further deplete.
Reduced dietary intake of fatty fish.
Essential Supplement Stack
Priority-ranked supplements based on depletion evidence
Recommended Additions
Additional supplements based on individual risk factors
Lab Monitoring Schedule
Recommended testing timeline while on this medication
Every 6-12 months, or as clinically indicated
Drug Interactions
5 known interactions to monitor
Both reduce B12 absorption. Combined use increases B12 deficiency risk.
Further reduces B12 and magnesium absorption
Vitamin K2 supplementation may affect INR
Delayed gastric emptying may alter levothyroxine absorption
CagriSema is a combination; using semaglutide alone would miss the synergistic effects and potentially different side effect profile.
CagriSema (Cagrilintide + Semaglutide)-Specific Notes
Important considerations unique to this medication
CagriSema combines semaglutide's GLP-1 agonism with cagrilintide's GLP-1 receptor co-targeting (as an amylin analog). It has shown superior weight loss and HbA1c reduction compared to semaglutide alone in Phase 2 trials (PMID: 40544433, PMID: 40544432). The potent GLP-1 receptor activation amplifies risks associated with semaglutide.
Nausea, vomiting, diarrhea are common, especially during dose titration. Choose supplement forms that minimize GI distress.
Take fat-soluble vitamins (D) with the largest meal. Take iron separately from calcium and coffee (2+ hours apart). Take magnesium before bed. Take thyroid medications 60+ minutes before any meal, on empty stomach.
Evidence Citations
8 PubMed-indexed studies referenced
Add this protocol to your profile
Your Daily Intelligence and Ask Dose will be personalized for the CagriSema (Cagrilintide + Semaglutide) protocol, including nutrient depletion alerts and interaction warnings.
Sign in required. Your health data stays encrypted and private.
This protocol is for educational purposes only and is not medical advice. Supplement recommendations are adjunctive support, not replacements for prescribed medication. Always consult your prescribing physician before adding supplements to your CagriSema (Cagrilintide + Semaglutide) regimen. Individual needs vary based on health status, diet, and concurrent medications. Scan Dose is not affiliated with any pharmaceutical manufacturer.
Scan Dose does not sell supplements or accept affiliate commissions. All content is independently researched.